NYSE:ANRO | Free Cash Flow | Alto Neuroscience, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2023-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$27.09M$556,000.00-$27.65M
2025-12-31-$11.52M$0.00-$11.52M
2025-03-31-$16.56M$24,000.00-$16.58M
2024-12-31-$13.02M$506,000.00-$13.53M
2024-03-31-$10.98M$224,000.00-$11.21M
2023-12-31-$11.52M$352,000.00-$11.88M
2023-03-31-$7.52M$21,000.00-$7.55M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$51.77M$24,000.00-$51.79M
2024-12-31-$47.42M$2.08M-$49.5M
2023-12-31-$33.45M$470,000.00-$33.92M